Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 349 matching trials from the live ClinicalTrials.gov search.
Conditions
Recurrent Uterine Sarcoma, Uterine Carcinosarcoma
Interventions
imatinib mesylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Refractory Malignancy, Solid Tumors
Interventions
Imatinib and PTK/ZK222584
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Chronic Myeloid Leukemia
Interventions
PEG-IFN-a2b
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
Docetaxel, Imatinib mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Conditions
Gastric Adenocarcinoma
Interventions
Gleevec, Taxotere
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Chronic Myelogenous Leukemia
Interventions
Zileuton
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Gastrointestinal Stromal Tumor
Interventions
regorafenib
Drug
Lead sponsor
Suzanne George, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • Portland, Oregon • Philadelphia, Pennsylvania
Conditions
B Acute Lymphoblastic Leukemia
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine
Procedure · Biological · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
366 Days to 46 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
143
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 121 more
Conditions
Advanced Gastrointestinal Stromal Tumor (GIST)
Interventions
BGJ398, Imatinib Mesylate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
7
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 4 more
Conditions
Lymphoblastic Leukemia, Acute
Interventions
Prednisone, Dexamethasone, Vincristine, Daunorubicin, Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase, Methotrexate, Cyclophosphamide, Cytarabine, Etoposide, Mercaptopurine, Imatinib, chemotherapy, intrathecal chemotherapy, steroid therapy, hematopoietic stem cell transplantation
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Months to 18 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
2
States / cities
Memphis, Tennessee • Fort Worth, Texas
Conditions
Leukemia
Interventions
dasatinib, imatinib mesylate
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Acute Lymphoblastic Leukemia
Interventions
Bortezomib, Vorinostat, Dexamethasone, Methotrexate, Imatinib mesylate
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
2 Years to 30 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Myeloid Leukemia, Chronic
Interventions
Dasatinib, Imatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
Docetaxel, Imatinib Mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Conditions
Recurrent Glioblastoma Multiforme (GBM)
Interventions
Imatinib tablets, Hydroxyurea capsules
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 1Phase 2 Interventional Results available

Imatinib in Systemic Sclerosis

NCT00506831
Conditions
Scleroderma, Systemic
Interventions
Imatinib mesylate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Stanford, California
Conditions
Breast Cancer
Interventions
gemcitabine hydrochloride, imatinib mesylate
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
9
States / cities
Chicago, Illinois • Baltimore, Maryland • Camden, New Jersey + 5 more
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study With Metformin and Imatinib

NCT01404715
Conditions
Healthy
Interventions
Metformin, Imatinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Francisco, California
Conditions
Chronic Phase Chronic Myeloid Leukemia
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Anaheim, California • Southington, Connecticut • Baltimore, Maryland + 2 more
Conditions
All Indications for Glivec/Gleevec and Tasigna
Interventions
Tasigna, Gleevec
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Wilmington, North Carolina
Conditions
Lymphangioleiomyomatosis (LAM), Lymphangioleiomyomatosis
Interventions
Imatimib Mesylate, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
New York, New York • Charleston, South Carolina
Conditions
Leukemia
Interventions
imatinib mesylate
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Interventions
Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
13
States / cities
Denver, Colorado • Fort Myers, Florida • Tallahassee, Florida + 9 more
Conditions
Myelogenous Leukemia, Chronic, Chronic Phase
Interventions
Gleevec
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Houston, Texas